Dermatology Trials

• 31/03/2027

  Adjuvant peginterferon alfa-2b for 2 years vs Observation in patients with an ulcerated primary cutaneous melanoma with T(2-4)bN0M0: A randomized phase III trial of the EORTC Melanoma Group

  View Trial

• 31/05/2021

  EczTend

  Long-term extension trial in subjects with atopic dermatitis who participated in previous tralokinumab trials – ECZTEND

  View Trial

• 31/03/2021

  Phase 4 Placebo Controlled Study of the Impact of Apremilast on Quality of Life Efficacy and Safety in Subjects with Manifestations of Plaque Psoriasis and Impaired Quality of Life

  View Trial

• 31/03/2022

  SUNRISE

  A randomized double-blind multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year) safety and tolerability of 2 subcutaneous secukinumab dose regimens in adult patients with moderate to severe hidradenitis suppurativa (SUNRISE)

  View Trial

• 31/07/2028

  BADBIR

  British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)

  View Trial

• 30/04/2021

  MOLGEN

  Molecular genetics of adverse drug reactions: from candidate genes to genome wide association studies.

  View Trial

• 31/03/2016

  A 52-week multicenter randomized double-blind placebo-controlled study of subcutaneous secukinumab to demonstrate efficacy as assessed by palmoplantar pustulosis Psoriasis Area and Severity Index (ppPASI) at 16 weeks of treatment compared to placebo and to assess long term safety tolerability and efficacy in subjects with moderate to severe chronic palmoplantar pustular psoriasis

  View Trial

• 31/03/2024

  BSTOP

  A multicentre prospective cohort study to establish clinically relevant pharmacogenetic markers of systemic treatment outcomes in patients with severe psoriasis

  View Trial

• 31/03/2022

  SOLAR: A Phase 2 Randomized Open-label Parallel-group Active Comparator Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects with Cutaneous T-Cell Lymphoma (CTCL) Mycosis Fungoides (MF) Subtype

  View Trial

• 30/04/2022

  PARCT

  Phase II trial of atezolizumab (anti-PD-L1) in the treatment of stage IIb-IV mycosis fungoides/sezary syndrome patients relapsed/refractory after a previous systemic treatment (PARCT)

  View Trial